Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 648

1.

A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer.

Gatti-Mays ME, Redman JM, Donahue RN, Palena C, Madan RA, Karzai F, Bilusic M, Sater HA, Marté JL, Cordes LM, McMahon S, Steinberg SM, Orpia A, Burmeister A, Schlom J, Gulley JL, Strauss J.

Oncologist. 2019 Oct 8. pii: theoncologist.2019-0608. doi: 10.1634/theoncologist.2019-0608. [Epub ahead of print]

PMID:
31594913
2.

Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK.

Giles AJ, Hao S, Padget M, Song H, Zhang W, Lynes J, Sanchez V, Liu Y, Jung J, Cao X, Fujii R, Jensen R, Gillespie D, Schlom J, Gilbert MR, Nduom EK, Yang C, Lee JH, Soon-Shiong P, Hodge JW, Park DM.

JCI Insight. 2019 Oct 17;4(20). pii: 130688. doi: 10.1172/jci.insight.130688.

3.

Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors.

Bilusic M, Heery CR, Collins JM, Donahue RN, Palena C, Madan RA, Karzai F, Marté JL, Strauss J, Gatti-Mays ME, Schlom J, Gulley JL.

J Immunother Cancer. 2019 Sep 5;7(1):240. doi: 10.1186/s40425-019-0706-x.

4.

Efficient Tumor Clearance and Diversified Immunity through Neoepitope Vaccines and Combinatorial Immunotherapy.

Lee KL, Benz SC, Hicks KC, Nguyen A, Gameiro SR, Palena C, Sanborn JZ, Su Z, Ordentlich P, Rohlin L, Lee JH, Rabizadeh S, Soon-Shiong P, Niazi K, Schlom J, Hamilton DH.

Cancer Immunol Res. 2019 Aug;7(8):1359-1370. doi: 10.1158/2326-6066.CIR-18-0620. Epub 2019 Jul 10.

PMID:
31292145
5.

Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12.

Morillon YM 2nd, Su Z, Schlom J, Greiner JW.

J Immunother Cancer. 2019 Jun 11;7(1):150. doi: 10.1186/s40425-019-0620-2.

6.

A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules.

Gatti-Mays ME, Strauss J, Donahue RN, Palena C, Del Rivero J, Redman JM, Madan RA, Marté JL, Cordes LM, Lamping E, Orpia A, Burmeister A, Wagner E, Pico Navarro C, Heery CR, Schlom J, Gulley JL.

Clin Cancer Res. 2019 Aug 15;25(16):4933-4944. doi: 10.1158/1078-0432.CCR-19-0183. Epub 2019 May 20.

PMID:
31110074
7.

Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis.

Allen CT, Lee S, Norberg SM, Kovalovsky D, Ye H, Clavijo PE, Hu-Lieskovan S, Schlegel R, Schlom J, Strauss J, Gulley JL, Trepel J, Hinrichs CS.

J Immunother Cancer. 2019 May 3;7(1):119. doi: 10.1186/s40425-019-0603-3.

8.

Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.

Sun L, Clavijo PE, Robbins Y, Patel P, Friedman J, Greene S, Das R, Silvin C, Van Waes C, Horn LA, Schlom J, Palena C, Maeda D, Zebala J, Allen CT.

JCI Insight. 2019 Apr 4;4(7). pii: 126853. doi: 10.1172/jci.insight.126853. eCollection 2019 Apr 4.

9.

Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.

Knudson KM, Hicks KC, Alter S, Schlom J, Gameiro SR.

J Immunother Cancer. 2019 Mar 21;7(1):82. doi: 10.1186/s40425-019-0551-y.

10.

Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells.

Friedman J, Padget M, Lee J, Schlom J, Hodge J, Allen C.

Oral Oncol. 2019 Mar;90:38-44. doi: 10.1016/j.oraloncology.2019.01.017. Epub 2019 Feb 1.

PMID:
30846174
11.

The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex.

Jochems C, Tritsch SR, Knudson KM, Gameiro SR, Rumfield CS, Pellom ST, Morillon YM, Newman R, Marcus W, Szeto C, Rabizadeh S, Wong HC, Soon-Shiong P, Schlom J.

Oncoimmunology. 2018 Nov 27;8(2):e1532764. doi: 10.1080/2162402X.2018.1532764. eCollection 2019.

12.

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.

Karzai F, VanderWeele D, Madan RA, Owens H, Cordes LM, Hankin A, Couvillon A, Nichols E, Bilusic M, Beshiri ML, Kelly K, Krishnasamy V, Lee S, Lee MJ, Yuno A, Trepel JB, Merino MJ, Dittamore R, Marté J, Donahue RN, Schlom J, Killian KJ, Meltzer PS, Steinberg SM, Gulley JL, Lee JM, Dahut WL.

J Immunother Cancer. 2018 Dec 4;6(1):141. doi: 10.1186/s40425-018-0463-2.

13.

Vaccines as an Integral Component of Cancer Immunotherapy.

Schlom J, Gulley JL.

JAMA. 2018 Dec 4;320(21):2195-2196. doi: 10.1001/jama.2018.9511. No abstract available.

14.

Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types.

Hicks KC, Fantini M, Donahue RN, Schwab A, Knudson KM, Tritsch SR, Jochems C, Clavijo PE, Allen CT, Hodge JW, Tsang KY, Schlom J, Gameiro SR.

Oncoimmunology. 2018 Jul 30;7(11):e1466018. doi: 10.1080/2162402X.2018.1466018. eCollection 2018.

15.

A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study.

Parsons JK, Pinto PA, Pavlovich CP, Uchio E, Kim HL, Nguyen MN, Gulley JL, Jamieson C, Hsu P, Wojtowicz M, Parnes H, Schlom J, Dahut WL, Madan RA, Donahue RN, Chow HS.

Eur Urol Focus. 2018 Sep;4(5):636-638. doi: 10.1016/j.euf.2018.08.016. Epub 2018 Sep 7.

PMID:
30197041
16.

Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1.

Mammen AL, Rajan A, Pak K, Lehky T, Casciola-Rosen L, Donahue RN, Lepone LM, Zekeridou A, Pittock SJ, Hassan R, Schlom J, Gulley JL.

Ann Rheum Dis. 2019 Jan;78(1):150-152. doi: 10.1136/annrheumdis-2018-213777. Epub 2018 Sep 5. No abstract available.

PMID:
30185415
17.

First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors.

Strauss J, Heery CR, Kim JW, Jochems C, Donahue RN, Montgomery AS, McMahon S, Lamping E, Marté JL, Madan RA, Bilusic M, Silver MR, Bertotti E, Schlom J, Gulley JL.

Clin Cancer Res. 2019 Jan 1;25(1):99-109. doi: 10.1158/1078-0432.CCR-18-1512. Epub 2018 Aug 21.

PMID:
30131389
18.

Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies.

Friedman J, Morisada M, Sun L, Moore EC, Padget M, Hodge JW, Schlom J, Gameiro SR, Allen CT.

J Immunother Cancer. 2018 Jun 21;6(1):59. doi: 10.1186/s40425-018-0374-2.

19.

Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site.

McGee HM, Daly ME, Azghadi S, Stewart SL, Oesterich L, Schlom J, Donahue R, Schoenfeld JD, Chen Q, Rao S, Fragoso RC, Valicenti RK, Canter RJ, Maverakis EM, Murphy WJ, Kelly K, Monjazeb AM.

Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1259-1270. doi: 10.1016/j.ijrobp.2018.04.038. Epub 2018 Apr 22.

20.

M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine.

Knudson KM, Hicks KC, Luo X, Chen JQ, Schlom J, Gameiro SR.

Oncoimmunology. 2018 Feb 14;7(5):e1426519. doi: 10.1080/2162402X.2018.1426519. eCollection 2018. Erratum in: Oncoimmunology. 2019 Feb 27;8(5):e1584435.

21.

Morphological changes induced by intraprostatic PSA-based vaccine in prostate cancer biopsies (phase I clinical trial).

Merino MJ, Pinto PA, Moreno V, Gil S, Schlom J, Gulley JL.

Hum Pathol. 2018 Aug;78:72-78. doi: 10.1016/j.humpath.2018.04.013. Epub 2018 Apr 30.

PMID:
29709495
22.

An IL-15 superagonist/IL-15Rα fusion complex protects and rescues NK cell-cytotoxic function from TGF-β1-mediated immunosuppression.

Fujii R, Jochems C, Tritsch SR, Wong HC, Schlom J, Hodge JW.

Cancer Immunol Immunother. 2018 Apr;67(4):675-689. doi: 10.1007/s00262-018-2121-4. Epub 2018 Feb 1.

23.

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors.

Strauss J, Heery CR, Schlom J, Madan RA, Cao L, Kang Z, Lamping E, Marté JL, Donahue RN, Grenga I, Cordes L, Christensen O, Mahnke L, Helwig C, Gulley JL.

Clin Cancer Res. 2018 Mar 15;24(6):1287-1295. doi: 10.1158/1078-0432.CCR-17-2653. Epub 2018 Jan 3.

24.

Combination therapy with an OX40L fusion protein and a vaccine targeting the transcription factor twist inhibits metastasis in a murine model of breast cancer.

Malamas AS, Hammond SA, Schlom J, Hodge JW.

Oncotarget. 2017 Aug 5;8(53):90825-90841. doi: 10.18632/oncotarget.19967. eCollection 2017 Oct 31.

25.

A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells.

David JM, Dominguez C, McCampbell KK, Gulley JL, Schlom J, Palena C.

Oncoimmunology. 2017 Jul 13;6(10):e1349589. doi: 10.1080/2162402X.2017.1349589. eCollection 2017.

26.

Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis.

Grenga I, Donahue RN, Gargulak ML, Lepone LM, Roselli M, Bilusic M, Schlom J.

Urol Oncol. 2018 Mar;36(3):93.e1-93.e11. doi: 10.1016/j.urolonc.2017.09.027. Epub 2017 Nov 2.

27.

Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824).

Jochems C, Tritsch SR, Pellom ST, Su Z, Soon-Shiong P, Wong HC, Gulley JL, Schlom J.

Oncotarget. 2017 Sep 8;8(43):75217-75231. doi: 10.18632/oncotarget.20680. eCollection 2017 Sep 26.

28.

Enhanced immunotherapy by combining a vaccine with a novel murine GITR ligand fusion protein.

Morillon YM 2nd, Hammond SA, Durham NM, Schlom J, Greiner JW.

Oncotarget. 2017 Sep 7;8(43):73469-73482. doi: 10.18632/oncotarget.20703. eCollection 2017 Sep 26.

29.

Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury.

Heery CR, Palena C, McMahon S, Donahue RN, Lepone LM, Grenga I, Dirmeier U, Cordes L, Marté J, Dahut W, Singh H, Madan RA, Fernando RI, Hamilton DH, Schlom J, Gulley JL.

Clin Cancer Res. 2017 Nov 15;23(22):6833-6845. doi: 10.1158/1078-0432.CCR-17-1087. Epub 2017 Aug 30.

30.

A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab.

Fujii R, Schlom J, Hodge JW.

J Neurosurg. 2018 May;128(5):1419-1427. doi: 10.3171/2017.1.JNS162610. Epub 2017 Jul 28.

31.

Immunotherapy biomarkers 2016: overcoming the barriers.

Gulley JL, Berzofsky JA, Butler MO, Cesano A, Fox BA, Gnjatic S, Janetzki S, Kalavar S, Karanikas V, Khleif SN, Kirsch I, Lee PP, Maccalli C, Maecker H, Schlom J, Seliger B, Siebert J, Stroncek DF, Thurin M, Yuan J, Butterfield LH.

J Immunother Cancer. 2017 Mar 21;5(1):29. doi: 10.1186/s40425-017-0225-6.

32.

ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody.

Jochems C, Hodge JW, Fantini M, Tsang KY, Vandeveer AJ, Gulley JL, Schlom J.

Int J Cancer. 2017 Aug 1;141(3):583-593. doi: 10.1002/ijc.30767. Epub 2017 May 19.

33.

Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody.

Fallon JK, Vandeveer AJ, Schlom J, Greiner JW.

Oncotarget. 2017 Mar 28;8(13):20558-20571. doi: 10.18632/oncotarget.16137.

34.

Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6/E7.

Tsang KY, Fantini M, Fernando RI, Palena C, David JM, Hodge JW, Gabitzsch ES, Jones FR, Schlom J.

Vaccine. 2017 May 2;35(19):2605-2611. doi: 10.1016/j.vaccine.2017.03.025. Epub 2017 Apr 4.

35.

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.

Heery CR, O'Sullivan-Coyne G, Madan RA, Cordes L, Rajan A, Rauckhorst M, Lamping E, Oyelakin I, Marté JL, Lepone LM, Donahue RN, Grenga I, Cuillerot JM, Neuteboom B, Heydebreck AV, Chin K, Schlom J, Gulley JL.

Lancet Oncol. 2017 May;18(5):587-598. doi: 10.1016/S1470-2045(17)30239-5. Epub 2017 Mar 31.

36.

Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.

Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, Lin AA, Schlom J, June CH, Sherwin SA.

J Immunother Cancer. 2017 Mar 21;5:22. doi: 10.1186/s40425-017-0222-9. eCollection 2017.

37.

Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody.

Donahue RN, Lepone LM, Grenga I, Jochems C, Fantini M, Madan RA, Heery CR, Gulley JL, Schlom J.

J Immunother Cancer. 2017 Feb 21;5:20. doi: 10.1186/s40425-017-0220-y. eCollection 2017.

38.

An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele.

Jochems C, Hodge JW, Fantini M, Fujii R, Morillon YM 2nd, Greiner JW, Padget MR, Tritsch SR, Tsang KY, Campbell KS, Klingemann H, Boissel L, Rabizadeh S, Soon-Shiong P, Schlom J.

Oncotarget. 2016 Dec 27;7(52):86359-86373. doi: 10.18632/oncotarget.13411.

39.

Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab.

Khanna S, Thomas A, Abate-Daga D, Zhang J, Morrow B, Steinberg SM, Orlandi A, Ferroni P, Schlom J, Guadagni F, Hassan R.

J Thorac Oncol. 2016 Nov;11(11):1993-2005. doi: 10.1016/j.jtho.2016.07.033. Epub 2016 Aug 17.

40.

The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells.

Jochems C, Fantini M, Fernando RI, Kwilas AR, Donahue RN, Lepone LM, Grenga I, Kim YS, Brechbiel MW, Gulley JL, Madan RA, Heery CR, Hodge JW, Newton R, Schlom J, Tsang KY.

Oncotarget. 2016 Jun 21;7(25):37762-37772. doi: 10.18632/oncotarget.9326.

41.

A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas.

Duggan MC, Jochems C, Donahue RN, Richards J, Karpa V, Foust E, Paul B, Brooks T, Tridandapani S, Olencki T, Pan X, Lesinski GB, Schlom J, Carson Iii WE.

Cancer Immunol Immunother. 2016 Nov;65(11):1353-1364. Epub 2016 Aug 31.

42.

Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody.

Nagaya T, Nakamura Y, Sato K, Harada T, Choyke PL, Hodge JW, Schlom J, Kobayashi H.

Oncotarget. 2017 Jan 31;8(5):8807-8817. doi: 10.18632/oncotarget.12410.

43.

The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy.

Roselli M, Formica V, Cereda V, Jochems C, Richards J, Grenga I, Orlandi A, Ferroni P, Guadagni F, Schlom J.

Oncoimmunology. 2016 May 19;5(7):e1188243. doi: 10.1080/2162402X.2016.1188243. eCollection 2016 Jul.

44.

Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial.

Heery CR, Madan RA, Stein MN, Stadler WM, Di Paola RS, Rauckhorst M, Steinberg SM, Marté JL, Chen CC, Grenga I, Donahue RN, Jochems C, Dahut WL, Schlom J, Gulley JL.

Oncotarget. 2016 Oct 18;7(42):69014-69023. doi: 10.18632/oncotarget.10883.

45.

Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy.

Farsaci B, Donahue RN, Grenga I, Lepone LM, Kim PS, Dempsey B, Siebert JC, Ibrahim NK, Madan RA, Heery CR, Gulley JL, Schlom J.

Cancer Immunol Res. 2016 Sep 2;4(9):755-65. doi: 10.1158/2326-6066.CIR-16-0037. Epub 2016 Aug 2.

46.

A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses.

Grenga I, Donahue RN, Lepone LM, Richards J, Schlom J.

Clin Transl Immunology. 2016 May 20;5(5):e83. doi: 10.1038/cti.2016.27. eCollection 2016 May.

47.

Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab.

Fujii R, Friedman ER, Richards J, Tsang KY, Heery CR, Schlom J, Hodge JW.

Oncotarget. 2016 Jun 7;7(23):33498-511. doi: 10.18632/oncotarget.9256.

48.

Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types.

Lepone LM, Donahue RN, Grenga I, Metenou S, Richards J, Heery CR, Madan RA, Gulley JL, Schlom J.

J Circ Biomark. 2016 Mar 10;5:5. doi: 10.5772/62322. eCollection 2016 Jan-Dec.

49.

Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.

Vandeveer AJ, Fallon JK, Tighe R, Sabzevari H, Schlom J, Greiner JW.

Cancer Immunol Res. 2016 May;4(5):452-62. doi: 10.1158/2326-6066.CIR-15-0176. Epub 2016 Feb 26.

Supplemental Content

Loading ...
Support Center